We use our own and third party cookies to offer you our services, customize and analyze your browsing and show you advertising related to your preferences. By continuing to browse, we consider that you accept its use. You can change the settings and get more information in the
Cervical cancer (CC) is common among young women and is caused, in almost 100% of cases, by human papillomavirus (HPV). It can be prevented through vaccination against HPV or by detecting precursor lesions using a smear test. Early-stage cervical cancer is treated surgically, while chemoradiotherapy or chemotherapy is used in advanced stages.
Cervical cancer (CC), cancer of the uterine cervix or cancer of the cervix is the presence of malignant (cancerous) cells in the tissues that form part of the cervix. The cervix or neck of the uterus is the lower portion of the uterus and connects the body of the uterus (uterine cavity) with the vagina.
As such, the cervix forms a channel that leads to the vagina and outside the body. The mucous membrane lining the cervix in the vicinity of the vagina is called the ectocervix, while the membrane lining the cervical canal up to the uterine cavity is called the endocervix. Most tumours develop where the ectocervix joins the endocervix.
Cervical cancer usually forms slowly over time. Before this cancer forms, the cells in the cervix undergo certain changes (dysplasia) until abnormal cells start to appear in the tissues of the cervix. Over time the abnormal cells eventually turn into cancer cells, multiply and spread into the deepest part of the uterine cervix and surrounding areas.
Types of Cervical Cancer
Cervical cancers and precancerous lesions are classified according to what the cells look like when observed under a microscope.
The main types of cervical cancer are:
Squamous cell carcinoma. This is by far the most common type of cervical cancer (90%). It develops from precancerous lesions in the external lining of the cervix, which consists of several layers of cells that shed (squamous epithelium) and develop into squamous cell cancers if they become malignant.
Adenocarcinoma. Much less frequently, the epithelium lining the internal portion of the cervical canal, which is formed by a single layer of glandular or mucus-secreting cells, becomes malignant and produces a glandular cell cancer or adenocarcinoma.
Malignant tumours that originate in other types of cell (muscle, blood vessels, stroma, hormone- or melanin-producing cells) are very rare and give rise to sarcomas, carcinomas, neuroendocrine tumours, melanomas, etc. Metastasis to the cervix (the growth of tumours that originally developed in another organ) are extremely rare.
Classification according to the size and spread
STAGE I. Microinvasive tumours that are invisible to the naked eye and can only be diagnosed by microscopy (Stage IA) or visible tumours that are still confined to the cervix (Stage IB).
STAGE II. Tumours that have spread into neighbouring tissues such as the ligaments that attach the cervix to the pelvic wall (parametrium) or the vagina.
STAGE III. Tumours that extend into the lower portion of the vagina (Stage IIIA) or the pelvic wall (Stage IIIB).
STAGE IV. Tumours that now affect the inside of the bladder or rectum (Stage IVA) or metastasis to distant organs (Stage IVB).
How many women does it affect?
Cervical cancer is the fourth most common cancer worldwide. Approximately 80% of cases are diagnosed in developing countries that do not have screening and prevention or vaccination programmes in place. In Europe, around 35,000 new cases are diagnosed each year (it affects 1 in 110 women at some point in their lifetime). The maximum prevalence is seen in women aged 45–55 years. Cervical cancer is the second most frequent cancer affecting women in Europe under the age of 45. In Spain, it is estimated to affect 7 in every 100,000 women. Around 2,100 new cases are diagnosed each year and it is responsible for about 800 deaths.
Cervical Cancer explained in first person
Appointment of Aureli Torné, Gynaecological Oncologist
We manage to cure well over two-thirds of cases thanks to the modern treatments currently available
Sorry this content wasn't helpful to you. Send us your comment and we will take it into account to continue improving.
Thanks for your help!
An error has occurred and we were unable to send your opinion, please try again later.
Substantiated information by:
Aureli Torné BladéGynaecologist
Lydia GabaMedical oncologist
María Jesús SánchezNurse
Àngels RovirosaSpecialist in Oncological Radiotherapy
Published: 21 February 2020
Updated: 21 February 2020
The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.
Receive the latest updates related to this content.
Thank you for subscribing!
If this is the first time you subscribe you will receive a confirmation email, check your inbox
An error occurred and we were unable to send your data, please try again later.